Arterial Duct Stenting in Congenital Heart Disease with Duct-Dependent Pulmonary Circulation

2010 ◽  
Vol 6 (3) ◽  
pp. 183-191
Author(s):  
Giuseppe Santoro ◽  
Biagio Castaldi ◽  
Gianpiero Gaio ◽  
Maria Teresa Palladino ◽  
Carola Iacono ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Circulation ◽  
Congenital Heart ◽  
Arterial Duct

Pulmonary artery growth following arterial duct stenting in congenital heart disease with duct-dependent pulmonary circulation

2009 ◽  
Vol 74 (7) ◽  
pp. 1072-1076 ◽  
Author(s):  
Giuseppe Santoro ◽  
Maria Teresa Palladino ◽  
Giovanbattista Capozzi ◽  
Carola Iacono ◽  
Maria Giovanna Russo ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Artery ◽  
Pulmonary Circulation ◽  
Congenital Heart ◽  
Arterial Duct

scholarly journals Fate of Hypoplastic Pulmonary Arteries After Arterial Duct Stenting in Congenital Heart Disease With Duct-Dependent Pulmonary Circulation

2015 ◽  
Vol 8 (12) ◽  
pp. 1626-1632 ◽  
Author(s):  
Giuseppe Santoro ◽  
Gianpiero Gaio ◽  
Giovanbattista Capozzi ◽  
Luca Giugno ◽  
Maria Teresa Palladino ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Circulation ◽  
Congenital Heart ◽  
Pulmonary Arteries ◽  
Arterial Duct

Shear Stress Exposure Measurements on the Motionless Fluid Diode Valve in the Pulmonary Position

2010 ◽  
Author(s):  
Tiffany Camp ◽  
Richard S. Figliola ◽  
Timothy A. Conover ◽  
T.-Y. Hsia
Keyword(s):  
Congenital Heart Disease ◽  
Shear Stress ◽  
Heart Disease ◽  
Pressure Gradient ◽  
Pulmonary Circulation ◽  
Congenital Heart ◽  
Pulmonary Insufficiency ◽  
Stress Exposure ◽  
Exposure Measurements

Pulmonary insufficiency is one of the consequences of congenital heart disease, and currently no permanent solution exists. The concept of a motionless diode valve to regulate the pulmonary circulation has been proposed and previously studied. The diode valve has shown the ability to regulate flow with levels of regurgitation and pressure gradient that are acceptable within the pulmonary circulation [1].

Prostaglandins in congenital heart disease—potential for confusion

1995 ◽  
Vol 5 (2) ◽  
pp. 202-203 ◽  
Author(s):  
R. John Madar ◽  
Tim J.D. Donaldson ◽  
Stewart Hunter
Keyword(s):  
Congenital Heart Disease ◽  
United Kingdom ◽  
Heart Disease ◽  
Congenital Heart ◽  
Prostaglandin E ◽  
The United Kingdom ◽  
Arterial Duct

the use of prostaglandians in maintaining the patency of the arterial duct in congenital heart disease is well established. Intravenous1-3 and ora12–4 administration has been used, although for acute use intravenous and possibly intraosseous5 routes are favored. Both prostaglandin E1 (alprostadil—ProstinVR: Upjohn)1,4 and prostaglandin E2 (dinoprostone—Prostin E2: Upjohn)2,3 are used for this purpose, although only prostaglandin E1 is licensed for this indication in the United Kingdom. Prostaglandin E1 costs approximately 8 times more than prostaglandin E2 (£56.96 versus £7.43 per vial).

Sign in / Sign up

Export Citation Format

Share Document